A novel peptide inhibitor attenuates C-reactive protein's pro-inflammatory effects in-vivo

I. Jialal, S. Devaraj, G. Smith, Kit Lam, P. R. Kumaresan

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background Higher levels of C-reactive protein (CRP) predict cardiovascular events and also portend a poorer prognosis in patients with acute coronary syndromes. Much in-vitro and in-vivo data support a role for CRP in atherogenesis. Methods Using the one-bead-one-compound (OBOC) combinatorial library method we have successfully identified peptides against human CRP that inhibit its biological effects in-vitro. Hence we tested the effect of the best characterized inhibitor (CRP-i2) on the effects of CRP in an appropriate animal model, Wistar rats. Results Treatment with CRP resulted in significant increase in superoxide anion, nuclear factor kappaB (NFκb) activity and the release of biomarkers of inflammation from macrophages compared to Wistar rats treated with human albumin (HuSA). Pre-treatment with the inhibitor, CRP-i2, resulted in a significant reduction in CRP induced superoxide anion, NFκb activity and biomarkers of inflammation. Also, there were no observed clinical or laboratory related adverse effects. Conclusions We demonstrate that our novel peptide inhibitor attenuates the proinflammatory effects of CRP in-vivo. Future studies will examine the long-term effects of this inhibitor on vascular pathobiology.

Original languageEnglish (US)
Pages (from-to)3909-3912
Number of pages4
JournalInternational Journal of Cardiology
Volume168
Issue number4
DOIs
StatePublished - Oct 9 2013

Fingerprint

C-Reactive Protein
Peptides
Superoxides
Wistar Rats
Biomarkers
Inflammation
Acute Coronary Syndrome
Blood Vessels
Albumins
Atherosclerosis
Animal Models
Macrophages
Therapeutics

Keywords

  • CRP
  • Inflammation
  • Macrophages

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

A novel peptide inhibitor attenuates C-reactive protein's pro-inflammatory effects in-vivo. / Jialal, I.; Devaraj, S.; Smith, G.; Lam, Kit; Kumaresan, P. R.

In: International Journal of Cardiology, Vol. 168, No. 4, 09.10.2013, p. 3909-3912.

Research output: Contribution to journalArticle

Jialal, I. ; Devaraj, S. ; Smith, G. ; Lam, Kit ; Kumaresan, P. R. / A novel peptide inhibitor attenuates C-reactive protein's pro-inflammatory effects in-vivo. In: International Journal of Cardiology. 2013 ; Vol. 168, No. 4. pp. 3909-3912.
@article{f374744ac7164eea896bd23deb8de7eb,
title = "A novel peptide inhibitor attenuates C-reactive protein's pro-inflammatory effects in-vivo",
abstract = "Background Higher levels of C-reactive protein (CRP) predict cardiovascular events and also portend a poorer prognosis in patients with acute coronary syndromes. Much in-vitro and in-vivo data support a role for CRP in atherogenesis. Methods Using the one-bead-one-compound (OBOC) combinatorial library method we have successfully identified peptides against human CRP that inhibit its biological effects in-vitro. Hence we tested the effect of the best characterized inhibitor (CRP-i2) on the effects of CRP in an appropriate animal model, Wistar rats. Results Treatment with CRP resulted in significant increase in superoxide anion, nuclear factor kappaB (NFκb) activity and the release of biomarkers of inflammation from macrophages compared to Wistar rats treated with human albumin (HuSA). Pre-treatment with the inhibitor, CRP-i2, resulted in a significant reduction in CRP induced superoxide anion, NFκb activity and biomarkers of inflammation. Also, there were no observed clinical or laboratory related adverse effects. Conclusions We demonstrate that our novel peptide inhibitor attenuates the proinflammatory effects of CRP in-vivo. Future studies will examine the long-term effects of this inhibitor on vascular pathobiology.",
keywords = "CRP, Inflammation, Macrophages",
author = "I. Jialal and S. Devaraj and G. Smith and Kit Lam and Kumaresan, {P. R.}",
year = "2013",
month = "10",
day = "9",
doi = "10.1016/j.ijcard.2013.06.047",
language = "English (US)",
volume = "168",
pages = "3909--3912",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",
number = "4",

}

TY - JOUR

T1 - A novel peptide inhibitor attenuates C-reactive protein's pro-inflammatory effects in-vivo

AU - Jialal, I.

AU - Devaraj, S.

AU - Smith, G.

AU - Lam, Kit

AU - Kumaresan, P. R.

PY - 2013/10/9

Y1 - 2013/10/9

N2 - Background Higher levels of C-reactive protein (CRP) predict cardiovascular events and also portend a poorer prognosis in patients with acute coronary syndromes. Much in-vitro and in-vivo data support a role for CRP in atherogenesis. Methods Using the one-bead-one-compound (OBOC) combinatorial library method we have successfully identified peptides against human CRP that inhibit its biological effects in-vitro. Hence we tested the effect of the best characterized inhibitor (CRP-i2) on the effects of CRP in an appropriate animal model, Wistar rats. Results Treatment with CRP resulted in significant increase in superoxide anion, nuclear factor kappaB (NFκb) activity and the release of biomarkers of inflammation from macrophages compared to Wistar rats treated with human albumin (HuSA). Pre-treatment with the inhibitor, CRP-i2, resulted in a significant reduction in CRP induced superoxide anion, NFκb activity and biomarkers of inflammation. Also, there were no observed clinical or laboratory related adverse effects. Conclusions We demonstrate that our novel peptide inhibitor attenuates the proinflammatory effects of CRP in-vivo. Future studies will examine the long-term effects of this inhibitor on vascular pathobiology.

AB - Background Higher levels of C-reactive protein (CRP) predict cardiovascular events and also portend a poorer prognosis in patients with acute coronary syndromes. Much in-vitro and in-vivo data support a role for CRP in atherogenesis. Methods Using the one-bead-one-compound (OBOC) combinatorial library method we have successfully identified peptides against human CRP that inhibit its biological effects in-vitro. Hence we tested the effect of the best characterized inhibitor (CRP-i2) on the effects of CRP in an appropriate animal model, Wistar rats. Results Treatment with CRP resulted in significant increase in superoxide anion, nuclear factor kappaB (NFκb) activity and the release of biomarkers of inflammation from macrophages compared to Wistar rats treated with human albumin (HuSA). Pre-treatment with the inhibitor, CRP-i2, resulted in a significant reduction in CRP induced superoxide anion, NFκb activity and biomarkers of inflammation. Also, there were no observed clinical or laboratory related adverse effects. Conclusions We demonstrate that our novel peptide inhibitor attenuates the proinflammatory effects of CRP in-vivo. Future studies will examine the long-term effects of this inhibitor on vascular pathobiology.

KW - CRP

KW - Inflammation

KW - Macrophages

UR - http://www.scopus.com/inward/record.url?scp=84886244030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886244030&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2013.06.047

DO - 10.1016/j.ijcard.2013.06.047

M3 - Article

VL - 168

SP - 3909

EP - 3912

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

IS - 4

ER -